Myo-inositol/D-chiro-inositol Ratio in Follicular Fluid
Launched by LO.LI.PHARMA S.R.L · Feb 13, 2017
Trial Information
Current as of May 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • clear follicular aspirate obtained during oocyte retrieval;
- • each specimen of follicular fluid containing only one oocyte.
- Exclusion Criteria:
- • hyperglycaemic women;
- • PCOS women also if euglycaemic;
- • diabetic subjects having low concentrations of detectable MI in association with an anomalous MI transport.
About Lo.Li.Pharma S.R.L
lo.li.pharma s.r.l. is a leading pharmaceutical company dedicated to the development and commercialization of innovative therapies aimed at improving patient outcomes across various therapeutic areas. With a strong commitment to research and development, lo.li.pharma s.r.l. leverages cutting-edge science and technology to advance clinical trials that address unmet medical needs. The company prides itself on its rigorous quality standards and collaborative approach, working closely with healthcare professionals, regulatory bodies, and research institutions to bring safe and effective treatments to market. Through its strategic initiatives, lo.li.pharma s.r.l. strives to enhance the well-being of patients worldwide while fostering sustainable growth in the pharmaceutical industry.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Thessaloniki, , Greece
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials